Join the 'Krystexxa' group to help and get support from people like you.
Posted 17 Aug 2011 by Drugs.com
CHICAGO, Aug. 16, 2011—As an alternative to a conventional treatment for gout that some patients may not respond to, patients with severe, chronic gout who received the medication pegloticase for 6 months had greater improvement in measures of uric acid levels as well as physical function and quality of life, according to a study in the August 17 issue of JAMA. Long-term urate (a salt derived from uric acid) lowering therapy in gout aims to maintain concentrations of uric acid (UA) below a certain level. However, it is common for UA levels to exceed a recommended goal urate range during oral urate-lowering therapy among the 5 to 6 million U.S. patients with gout, according to background information in the article. Although available oral urate-lowering agents can achieve target UA in most patients, urate-lowering therapy fails for perhaps 3 percent of patients because of refractoriness ( ... Read more
Posted 16 Aug 2011 by Drugs.com
TUESDAY, Aug. 16 – For some gout patients afflicted with a particularly severe, crippling form of the disease who find standard treatments either intolerable or ineffective, a recently approved alternative appears to afford relief. A new injectable treatment called pegloticase (brand name Krystexxa) has no effect on most severe gout patients, but researchers say that for the roughly four in 10 patients who do respond positively, the improvement can be significant. Use of pegloticase was approved by the U.S. Food and Drug Administration in September 2010. However, the treatment is expensive and the study found a high rate of side effects, some extremely serious, suggesting that health providers have to weigh the costs and benefits on a case by case basis. "What we're focusing on here are the approximately 3 percent of gout patients who have the most advanced form of disease," said study ... Read more